What are the recommended famciclovir dosing regimens for herpes zoster, recurrent genital herpes (including renal dose adjustments), recurrent herpes labialis, and prophylaxis in dialysis patients, and are there any contraindications related to the zoster vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Famciclovir Dosing Recommendations

Famciclovir is an effective oral antiviral agent with well-established dosing regimens for herpes zoster, recurrent genital herpes, and herpes labialis, with specific renal dose adjustments required for patients with impaired kidney function, including those on dialysis.

Herpes Zoster (Shingles)

Standard Dosing:

  • 500 mg orally every 8 hours for 7 days 1
  • Initiate therapy as soon as herpes zoster is diagnosed, ideally within 72 hours of rash onset 1

Renal Dose Adjustments for Herpes Zoster:

  • CrCl ≥60 mL/min: 500 mg every 8 hours
  • CrCl 40-59 mL/min: 500 mg every 12 hours
  • CrCl 20-39 mL/min: 500 mg every 24 hours
  • CrCl <20 mL/min: 250 mg every 24 hours
  • Hemodialysis: 250 mg following each dialysis session 1

The evidence demonstrates comparable efficacy between famciclovir and acyclovir for herpes zoster treatment 2. Famciclovir offers the advantage of less frequent dosing (three times daily vs. five times daily for acyclovir), which may improve adherence 3.

Recurrent Genital Herpes

Episodic Treatment (Immunocompetent Patients)

Standard Dosing:

  • 1000 mg orally twice daily for 1 day 1
  • Initiate at the first sign or symptom (tingling, itching, burning, pain, or lesion)

Renal Dose Adjustments for Single-Day Treatment:

  • CrCl ≥60 mL/min: 1000 mg twice daily for 1 day
  • CrCl 40-59 mL/min: 500 mg twice daily for 1 day
  • CrCl 20-39 mL/min: 500 mg single dose
  • CrCl <20 mL/min: 250 mg single dose
  • Hemodialysis: 250 mg single dose following dialysis 1

Suppressive Therapy (Immunocompetent Patients)

Standard Dosing:

  • 250 mg orally twice daily 1
  • Continue for up to 1 year, then reassess recurrence frequency

Renal Dose Adjustments for Suppressive Therapy:

  • CrCl ≥40 mL/min: 250 mg every 12 hours
  • CrCl 20-39 mL/min: 125 mg every 12 hours
  • CrCl <20 mL/min: 125 mg every 24 hours
  • Hemodialysis: 125 mg following each dialysis session 1

Important Caveat: The efficacy and safety of famciclovir for suppression beyond 1 year have not been established 1. After 1 year of continuous therapy, consider discontinuation to reassess the patient's natural recurrence rate.

HIV-Infected Patients

Standard Dosing:

  • 500 mg orally twice daily for 7 days 1
  • Initiate at first sign or symptom of recurrent orolabial or genital herpes

Renal Dose Adjustments for HIV-Infected Patients:

  • CrCl ≥40 mL/min: 500 mg every 12 hours
  • CrCl 20-39 mL/min: 500 mg every 24 hours
  • CrCl <20 mL/min: 250 mg every 24 hours
  • Hemodialysis: 250 mg following each dialysis session 1

Recurrent Herpes Labialis (Cold Sores)

Standard Dosing:

  • 1500 mg orally as a single dose 1
  • Initiate at the first sign or symptom (tingling, itching, burning, pain, or lesion)

Renal Dose Adjustments for Herpes Labialis:

  • CrCl ≥60 mL/min: 1500 mg single dose
  • CrCl 40-59 mL/min: 750 mg single dose
  • CrCl 20-39 mL/min: 500 mg single dose
  • CrCl <20 mL/min: 250 mg single dose
  • Hemodialysis: 250 mg single dose following dialysis 1

The single-dose regimen offers exceptional convenience and has demonstrated efficacy comparable to or better than other treatments in healing time and pain resolution 4, 5.

Critical Dosing Considerations for Dialysis Patients

For all hemodialysis patients:

  • Administer famciclovir following each dialysis session 1
  • This timing is critical because famciclovir and its active metabolite penciclovir are removed by hemodialysis
  • The dose varies by indication (see specific doses above)
  • Do not administer doses between dialysis sessions unless specifically indicated by the adjusted regimen

Warning: Cases of acute renal failure have been reported in patients with underlying renal disease who received inappropriately high doses of famciclovir for their level of renal function 1. Always calculate creatinine clearance and adjust doses accordingly.

Zoster Vaccine Considerations

There is no contraindication between famciclovir use and zoster vaccination 6. Key points:

  • Zoster vaccine is recommended for all persons aged ≥60 years (or ≥50 years for recombinant zoster vaccine) 6, 7
  • Prior episode of herpes zoster is not a contraindication to vaccination 6, 7
  • Wait at least 2 months after an acute herpes zoster episode before administering zoster vaccine 7
  • Patients do not need to discontinue famciclovir suppressive therapy before receiving zoster vaccine
  • The vaccine can prevent future episodes and reduce the risk of postherpetic neuralgia 6, 8

Administration Guidelines

  • Famciclovir may be taken with or without food 1
  • No serologic testing or history verification is required before prescribing
  • Therapy should be initiated as early as possible for maximum benefit
  • For herpes zoster: start within 72 hours of rash onset 1
  • For recurrent episodes: start at first prodromal symptom 1

References

Research

Famciclovir for treatment of herpesvirus infections.

The Annals of pharmacotherapy, 1996

Research

Single-dose famciclovir for the treatment of herpes labialis.

Current medical research and opinion, 2006

Research

Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 2008

Guideline

recommendations and guidance for herpes zoster vaccination for adults in taiwan.

Journal of Microbiology, Immunology and Infection, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.